Higashimurayama, Japan

Ryohei Sekimoto

USPTO Granted Patents = 3 


 

Average Co-Inventor Count = 8.6

ph-index = 1

Forward Citations = 2(Granted Patents)


Location History:

  • Higashimurayama, JP (2014)
  • Osaka, JP (2016)

Company Filing History:


Years Active: 2014-2016

Loading Chart...
Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Ryohei Sekimoto: Innovator in Pharmaceutical Chemistry

Introduction

Ryohei Sekimoto is a notable inventor based in Higashimurayama, Japan. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that target various health conditions.

Latest Patents

Sekimoto holds 3 patents that focus on phenylpyridine derivatives. His latest patents include a compound that exhibits both angiotensin II receptor antagonism and PPARγ activation effects. This compound is useful as a preventative and therapeutic agent for high blood pressure, cardiac disease, arteriosclerosis, and type-2 diabetes. The general formula of the compound includes specific structural components such as a pyridine ring and a tetrazole ring, which contribute to its medicinal properties.

Career Highlights

Ryohei Sekimoto is associated with Kowa Company Limited, where he continues to innovate in the pharmaceutical sector. His work has led to the development of novel compounds that are essential in treating various metabolic and cardiovascular diseases.

Collaborations

Throughout his career, Sekimoto has collaborated with esteemed colleagues such as Toru Miura and Seiichi Sato. These partnerships have enhanced the research and development of effective pharmaceutical solutions.

Conclusion

Ryohei Sekimoto's contributions to pharmaceutical chemistry through his innovative patents and collaborations highlight his role as a key inventor in the industry. His work continues to impact the field positively, providing valuable therapeutic options for patients.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…